FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPR	OVAL
OMB Number:	3235-0287
Estimated average I	burden
hours par response	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)													
1. Name and Address of Reporting Person* Curd John G (Last) (First) (Middle) C/O THRESHOLD PHARMACEUTICALS, INC., 1300 SEARPORT BLVD. SUITE 500			2. Issuer Name and Ticker or Trading Symbol THRESHOLD PHARMACEUTICALS INC [THLD] 3. Date of Earliest Transaction (Month/Day/Year) 01/09/2009							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director M. Officer (give title below) Director Other (specify below)					
										President and CMO					
(Street) REDWOOD CITY, CA 94063			4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person					
(Cit		(State)	(Zip)			Ta	ble I	- Non-Deri	ivative Securitie	es Acquir	ed, Disposed	of, or Bene	ficially Owne	d	
1.Title of S (Instr. 3)	Security		2. Transaction Date (Month/Day/Year)		on D	Date, if (8) (1. Securities Acq A) or Disposed of Instr. 3, 4 and 5) (A) or Amount (D)	of (D) O	Amount of Sound Follow ransaction(s) (nstr. 3 and 4)	ing Reporte	d (Ownership of Be Oirect (D) or Indirect (II	Nature Indirect eneficial wnership nstr. 4)
			Table II -					in this display uired, Disp	ns who respon form are not r ys a currently osed of, or Bend onvertible secur	equired valid ON	to respond IB control r	unless the		JLC 14	74 (9-02)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	se (Month/Day/Year)	3A. Deemed Execution Date, if	4. Transaction Code		5. Number		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownership Form of Derivative Security: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)
							4,								
				Code	V		4, (D)	Date Exercisable	Expiration e Date	Title	Amount or Number of Shares				

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director 10% Owner		Officer	Other		
Curd John G C/O THRESHOLD PHARMACEUTICALS, INC. 1300 SEARPORT BLVD. SUITE 500 REDWOOD CITY, CA 94063			President and CMO			

Signatures

John G. Curd by Joel Fernandes, Attorney-In-Fact	01/14/2009
**Signature of Reporting Person	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a)
- (1) The option vests monthly over a period of four years.
- (2) The stock option was granted pursuant to the Threshold Pharmaceuticals, Inc. 2004 Amended and Restated Equity Incentive Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.